.png){kind=icon}
.png){kind=icon}
Return
Inhaled protein nanoparticles achieve synergistic therapy for idiopathic pulmonary fibrosis via reprogramming the ROS/TGF‑β1/SMAD pathway
.png){kind=icon}
PRE
AI
G
Y
F
Z
B
P
Z
C
W
S
梅
H
DOI：10.1016/j.nantod.2026.103127.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Inhaled protein nanoparticles (HbRT) are engineered for synergistic IPF therapy. • HbRT exerts a dual-targeting effect on the ROS/TGF-β1/SMAD signaling pathway. • HbRT alleviates oxidative stress, inflammation, EMT, and fibroblast activation. • Inhaled HbRT demonstrates potent efficacy in a bleomycin-induced IPF mouse model. • Inhaled HbRT demonstrates potent efficacy in human pulmonary fibrosis organoids.
Journal
IF:
10.9
Papers:
3.0K
Citations:
2.1W
Organization
Cited Papers